The consistent cytogenetic translocation of chronic myelogenous leukemia (the Philadelphia chromosome, Ph') has been observed in cells of multiple hematopoietic lineages. This translocation creates a chimeric gene composed of breakpoint-cluster-region (bcr) sequences from chromosome 22 fused to a portion of the abI oncogene on chromosome 9. The resulting gene product (P210c-ab1) resembles the transforming protein of the Abelson murine leukemia virus in its structure and tyrosine kinase activity. P210c-abl is expressed in Ph'-positive cell lines of myeloid lineage and in clinical specimens with myeloid predominance. We show here that Epstein-Barr virus-transformed B-lymphocyte lines that retain Ph' can express P210c abl. The level of expression in these B-cell lines is generally lower and more variable than that observed for myeloid lines. Protein expression is not related to amplification of the abI gene but to variation in the level of ber-abl mRNA produced from a single Ph' template.
translocation breakpoints are variable, an RNA-splicing mechanism generates a very similar 8-kilobase (kb) mRNA in each case (5) (6) (7) (8) (9) . The hybrid bcr-abl message encodes a structurally altered form of the abl oncogene product, called P210c-abl (10) (11) (12) (13) , with an amino-terminal segment derived from a portion of the exons of bcr on chromosome 22 and a carboxyl-terminal segment derived from a major portion of the exons of the c-abl gene on chromosome 9. The chimeric structure of bcr-abl and the resulting P210c-abl is similar to the structure of the Abelson murine leukemia virus gag-abl genome and resulting P160v-abl transforming gene product.
Both proteins have very similar tyrosine kinase activities (10, 11, 14) which can be distinguished by their relative stability to denaturing detergents and by their ATP requirements from the recently described tyrosine kinase activity of the c-abl gene product (15) .
In concert with structural modification of the aminoterminal portion of the abl gene, increased level of expression has been implicated in activation of c-abl oncogenic potential. Myeloid and erythroid cell lines and clinical samples derived from acute-phase CML patients contain about 10-fold higher levels ofthe 8-kb bcr-abl mRNA and P210`cabl than the c-abl mRNA forms (6 and 7 kb) and P145c-abl gene product (5, 8, 9, 11) . The higher level of expression of the chimeric bcr-abl message in acute-phase cells is not likely to be solely due to the presence of the bcr promoter sequences at the 5' end of the gene, since the normal 4.5-kb and 6.7-kb bcrencoded mRNA species are expressed at an even lower level than the normal c-abl messages (5, 6) .
We have analyzed a series of Epstein-Barr virus-immortalized B-lymphoid cell lines derived from CML patients (16 
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supplemented with 5% dialyzed fetal bovine serum. Cells were then resuspended in 2 ml of the minimal medium. Labeling was started with the addition of [32P]orthophosphate (1 mCi/ml; ICN; 1 Ci -37 GBq) and continued at 370C for 3-4 hr.
Immunoprecipitation and Immunoblottipg. Immunoprecipitations were carried out as described (10) . Cells'(1.5 x 1Q7) were washed with phosphate-buffered saline and extracted with 3-5 ml of phosphate lysis buffer (1% Triton X-100/0.1 NaDodSO4/0.5% deoxycholate/10 mM Na2HPO4, pH 7.5/ 100 mM NaCI) with 5 mM EDTA and 5 mM phenylmethylsulfonyl fluoride. Extracts were clarified by centrifugation and precipitated with normal or rabbit anti-abl sera (antipEX-2 or anti-pEX-5) (17) . The precipitated proteins were electrophoresed in a NaDodSO4/8% polyacrylamide gel.
32P-labeled proteins were detected by autoradiography.
Alternatively, abl proteins were detected by immunoblotting. Extracts from unlabeled cells were clarified, and proteins were concentrated by immunoprecipitation with rabbit antisera against abl-encoded proteins [anti-pEX-2 and anti-pEX-5 combined (17) ] and then fractionated in 8% acrylamide gels.
The proteins were transferred from the gel to nitrocellulose filters, using protease-facilitated transfer (18) . The ablencoded proteins were detected using murine monoclonal antibodies as a probe and peroxidase-conjugated goat antimouse second stage antibody (Bio-Rad) for development. Rabbit antisera and mouse monoclonal antibodies to abl proteins were prepared using bacterially expressed regions of the v-abl protein as immunogens (17, 19) . Anti-pEX-2 antibodies react with the internal tyrosine kinase domain and anti-pEX-5 antibodies react with the carboxyl-terminal segment of the abl proteins.
RNA Analysis. RNA was extracted from 101 cells by the NaDodSO4/urea/phenol method (20) . Polyadenylylated RNA wag purified by oligo(dT) affinity chromatography. Samples were electrophoresed in a 1% agarose/formaldehyde gel and transferred to nitrocellulose. abl RNA species were detected by hybridization with a nick-translated v-abl fragment probe (21) .
DNA Analysis. DNA was prepared from 5 X 107 cells of each cell line and processed for Southern blots with a v-abl probe as described (21) . (Fig. 1) . The normal c-abl protein P145c-abl was detected at a similar level in multiple Phl-positive and Ph'-negative cell lines. P210c-abl was only detected in the Ph'-positive cell lines because the bcr-abl chimeric gene which encodes P210c-abl resides on the Ph' (4, 5, 11, 13) . The level of P210Cab1 was, about 4-to 5-fold higher than the level of P145c-atl-in the SK-CML7Bt-33 cell line (Fig. IA, +) . The Ph'-positive eirthroid-pr'ogenitor cell line K562 (C) showed a level of P210jcab1 about 10-fold higher than P145c-ab1. However, the level of P210c'ab1 was about one-fifth that of P145c-abl in the Ph'-positive SK-CML16Bt-1 cell line (Fig. 1B,   + hr and then were extracted and clarified by centrifugation. Samples were immunoprecipitated with control normal serum (lanes 1), anti-pEX-2 (lanes 2), or anti-pEX-5 (lanes 3) and analyzed by NaDodSO4/8% PAGE followed by autoradiography with an intensifying screen (3 days for A and C, 10 days for B).
RESULTS
phase CML patients, in which P210c-abl was detected at a 10-fold higher level than P145c-abl (refs. 10 and 11; Table 1 ). There was no large difference in level of chimeric mRNA and P210c-abl expressed in four myeloid/erythroid-lineage Ph'-positive cell lines (K562, EM2, EM3, CML22, and BV173; refs. 9 and 11), despite a 4-to 5-fold amplification of abl-related sequences in the K562 cell line.
Detection of different levels of P210c-abl in Fig. 1 Fig. 2A, +) had a higher level of P210c-abl than P145, similar to the results with metabolic labeling (Fig. 1) . We did not detect P210C-abl by immunoblotting with 2 x 107 cells of line SK-CML8Bt-3 (Fig. 2B, +) . Reconstruction experiments using dilutions of cell extracts showed that we could detect about 5-10% the level of P210c-abl expressed in the K562 cell line (data not shown). We infer that the steady-state level of P2101cab1 in SK-CML8Bt-3 is lower than the level in SK-CML7Bt-33 by a factor of at least 10. The level of P210c-abl detected in these assays correlated with the amount of P210c-abl tyrosine kinase activity that could be detected in vitro (data not shown).
Dierent Levels of Pj2101c'a Are Reflected in the Amount of Stable bcr-abl mRNA. To identify the basis for detection of variable levels of P210C-abl, we examined the production of the abl RNA. RNA blot hybridization analysis using a v-abl probe (Fig. 3) showed that the normal 6-and 7-kb c-abl mRNAs were present at a similar level in Ph'-positive and -negative cell lines derived from different patients. However, the 8-kb mRNA that encodes P210c-abl was detected at a 10-fold higher level in SK-CML7Bt-33 (Fig. 3A, +) Fig. 1 . B-cell lines derived from blast-crisis and accelerated-phase patients had levels of P210 3-to 5-fold higher (+ + +) than levels of P145. Chronicphase-derived cell lines had P210 levels lower than orjust equivalent (+) to the level of P145. Myeloid and erythroid lines had levels of P210 5-to 10-fold higher than P145 (+ + + + +).
$Eight-kilobase bcr-abl mRNA detected as described in legend to Fig. 2 . Symbols: ±, borderline detectable; + + + + +, level of 8-kb mRNA 5-to 10-fold higher than that of the 6-and 7-kb c-abl mRNA species; + + +, level of 8-kb mRNA 3-to 5-fold higher than that of the 6-and 7-kb species; +, a level approximately equivalent to that of the 6-and 7-kb messages.
data not shown). There was no difference in the copy number of abl-related sequences as judged by Southern blot analysis (Fig. 4) . Only the K562 cell line control showed an amplification of abl sequences, as previously reported (22, 23) . These combined data suggest that differential bcr-abl mRNA expression from a single gene template is responsible for the variable levels of P210c-abl detected. This could be mediated CML8BN-10 (B,-) , and SK-CML8Bt-3 (B,+) were concentrated by immunoprecipitation with anti-pEX-2 plus anti-pEX-5. Samples were then electrophoresed in a NaDodSO4/8% polyacrylamide gel and transferred to nitrocellulose, using protease-facilitated transfer (18) . abl proteins were detected using a mixture of two monoclonal antibodies directed against the pEX-2 and pEX-5 abl-protein fragments produced in bacteria (19) as a probe and a peroxidase-conjugated goat anti-mouse second-stage antibody (Bio-Rad) for development. populations that lack the Ph' marker, supports a secondary or complementary role for Ph' in the progression of the disease (24, 25) . This chromosome marker is found in chronic, accelerated, and blast-crisis phases of the disease. It is likely that Ph' confers some growth advantage, since cells with the marker chromosome eventually predominate the marrow and peripheral blood even in chronic phase. During the phase of blast crisis, many patients develop additional chromosome abnormalities, including duplication of Ph', a variety of trisomies, and complex translocations (26) . This is suggestive evidence for Ph' being a necessary but not sufficient genetic change for the full evolution of the disease.
The realization that one molecular result of Ph' is the generation of a chimeric ber-abl protein with functional characteristics and structure analogous to the gag-abl transforming protein of the Abelson murine leukemia virus strengthens the argument for an important role of Ph' in the pathogenesis of CML. Although the Abelson virus is generally considered a rapidly transforming retrovirus, its effects can range from overcoming growth factor requirements, to cellular lethality, to induction of highly oncogenic tumors in a number of hematopoietic cell lineages (27, 28) . Even in the transformation of murine cell targets, there are several lines of evidence that suggest that the growth-promoting activity of the v-abl gene product is complemented by further cellular changes in the production of the malignant-cell phenotype (29) (30) (31) .
The regulation of bcr-abl gene expression is complex because the 5' end of the gene is derived from the non-abl sequences, bcr, normally found on chromosome 22 (6) . The level of stable message for the normal bcr gene and the normal abl gene are both much lower than the level of the bcr-abl message and protein from cell lines and clinical specimens derived from myeloid blast-crisis patients (5, 6, 11 (9) . Others have reported chronic-phase patients with variable but, in some cases, relatively high levels of the bcr-abl mRNA (32) . The sampling variation and the heterogenous mixture of cell types in clinical samples complicate such analyses. Further work is needed to evaluate whether there is a defined change in P210c-abl expression during the progression of CML. It is interesting to note that among the limited sample of Ph'-positive B-cell lines we have examined (Table 1) , we have seen higher levels of P210c-abl in those derived from patik at more advanced stages of the disease.
It will be important to search for cell-type-specific mechanisms that might regulate expression of bcr-abl from Ph'.
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